Molnupiravir May Offer Modest 6-Month Benefits for High-Risk COVID Patients
Secondary analysis of trial data consistent with observational studies
Related Articles
BHIVA Spring Conference 2025
The BHIVA Spring Conference is moving to Brighton for 2025! We will as usual have a packed, relevant and high-quality scientific programme for attendees along…
Injectable antiretrovirals: real world or ideal world?
Following on the results of formal randomised clinical trials, real-world data can provide important insights into the safety and efficacy of a new drug regimen…
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort
Switching to cabotegravir and rilpivirine was not associated with a higher risk of loss of virological control among individuals without previous virological failure compared with…
Cambodia reports its first H5N1 death in 2025 – Khmer Times
A 28-year-old man from southeast Cambodia’s Kampong Cham province died of H5N1 human avian influenza on Friday, becoming the first death in 2025, the Ministry…
Decline in global vaccination rate ‘is very concerning,’ says WHO Chief | CNN
Christiane Amanpour speaks with Director-General of the World Health Organization, Tedros Adhanom Ghebreyesus, about the global health challenges in 2025.
Immune 87: When the immune system misbehaves
Immune discusses basophils as regulators of of lung inflammation over space and time, and neoself-antigens as the primary target for autoreactive T cells in human…
Outbreak of suspected Marburg Virus Disease– United Republic of Tanzania
When autocomplete results are available use up and down arrows to review and enter to select. On 13 January 2025, WHO informed its Member States…
CARB-X funds rapid diagnostic test platform for bloodstream infections
The $3.5 million award will support development of Melio’s rapid, culture-free diagnostic testing platform.
4 in 10 Minnesota COVID survivors report having at least 1 lingering symptom
Participants who received at least 1 COVID-19 vaccine booster dose had a 30% lower risk of long-COVID symptoms than their unvaccinated peers.
China reports infections from H9N2, H10N3 avian flu
As sporadic H9N2 infections continue, China’s number of more rare H10N3 infections over the past few years is now at four.
